FDA Grants Chelsea Therapeutics Orphan Drug Designation for Droxidopa (PrimeNewswire via Yahoo! Finance)
CHARLOTTE, N.C., Jan. 22, 2007 -- Chelsea Therapeutics International, Ltd. announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Primary Autonomic Failure, a group of diseases that includes Parkinson's Disease, Pure Autonomic Failure and ...

FDA Approves 18-Month Shelf Life For TAXUS(R) Stent System (Medical News Today)
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS(R) Express(2)(TM) paclitaxel-eluting coronary stent system in the United States to 18 months from the current shelf life of 12 months. [click link for full article]